Extended-spectrum β-lactamases (ESBL) 성질을 가진 세균에 의한 요로감염
Extended-spectrum β-lactamases Producing Bacteria in Urinary Tract Infection
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Multi-drug-resistant Enterobacteriaceae that produce extended-spectrum β-lactamases (ESBLs) have emerged in the communities and hospitals. Because β-lactamases are bacterial enzymes that hydrolyze β-lactamring in antibiotics, cephalosporins are not usually effective. Most ESBLs can be divided into three groups: TEM, SHV, and CTX-M. Recently, AmpC β-lactamase is included in this category. The clinical significance of ESBL bacteria is well known. Initially, ESBL bacteria exhibitmulti-drug resistance, such as co-trimoxazole, tetracycline, gentamicin, and fluroquinolone, as well as broad-spectrum cephalosporins. In addition, they can be transmitted to other places andother people. Moreover, inappropriate empirical therapy to urinary tract infection secondary to ESBL bacteria is usually associated with higher mortality. For these reasons, gram-negative pathogens that produce ESBLs remain an important cause oftherapy failure with newly developed cephalosporins, and incur serious complications and have consequences in infection control in the community. Consequently, it is an urgent issue to understand the characteristics of ESBL bacteria to minimize their spread and to treat ESBL associated urinary tract infection. We herein review the clinical significances of ESBL bacteria in urinary tract infection.
Abstract
Multi-drug-resistant Enterobacteriaceae that produce extended-spectrum β-lactamases (ESBLs) have emerged in the communities and hospitals. Because β-lactamases are bacterial enzymes that hydrolyze β-lactamring in antibiotics, cephalosporins are not usually effective. Most ESBLs can be divided into three groups: TEM, SHV, and CTX-M. Recently, AmpC β-lactamase is included in this category. The clinical significance of ESBL bacteria is well known. Initially, ESBL bacteria exhibitmulti-drug resistance, such as co-trimoxazole, tetracycline, gentamicin, and fluroquinolone, as well as broad-spectrum cephalosporins. In addition, they can be transmitted to other places andother people. Moreover, inappropriate empirical therapy to urinary tract infection secondary to ESBL bacteria is usually associated with higher mortality. For these reasons, gram-negative pathogens that produce ESBLs remain an important cause oftherapy failure with newly developed cephalosporins, and incur serious complications and have consequences in infection control in the community. Consequently, it is an urgent issue to understand the characteristics of ESBL bacteria to minimize their spread and to treat ESBL associated urinary tract infection. We herein review the clinical significances of ESBL bacteria in urinary tract infection.
참고문헌 (29)
- Jackson RW, "Bacterial pathogen evolution: breaking news", Trends Genet, 27, pp.32~40 (2011)
- Chan VL, "Bacterial genomes and infectious diseases", Pediatr Res, 54, pp.1~7 (2003)
- Khawcharoenporn T, "Risk factors for community-associated methicillin- resistant Staphylococcus aureus cellulitis-and the value of recognition", Hawaii Med J, 69, pp.232~236 (2010)
- Stefani S, "Methicillin-resistant Staphylococcus aureus: related infections and antibiotic resistance", Int J Infect Dis, 14(4), pp.19~22 (2010)
- Pitout JD, "Infections with extended-spectrum beta- lactamase-producing enterobacteriaceae: changing epidemiology and drug treatment choices", Drugs, 70, pp.313~333 (2010)
- Pitout JD, "Extended-spectrum beta-lactamase- producing Enterobacteriaceae: an emerging public-health concern", Lancet Infect Dis, 8, pp.159~166 (2008)
- Pfeifer Y, "Resistance to cephalosporins and carbapenems in Gram-negative bacterial pathogens", Int J Med Microbiol, 300, pp.371~379 (2010)
- Schwaber MJ, "Containment of a Countrywide Outbreak of Carbapenem-Resistant Klebsiella pneumoniae in Israeli Hospitals via a Nationally Implemented Intervention", Clin Infect Dis, 11 (2011)
- Adam HJ, "The Canadian Antimicrobial Resistance Alliance (CARA). Prevalence of antimicrobial resistant pathogens from blood cultures from Canadian hospitals: results of the CANWARD 2007-2009 study", Diagn Microbiol Infect Dis, 69, pp.307~313 (2011)
- Ehlers MM, "Detection of blaSHV, blaTEM and blaCTX-M antibiotic resistance genes in randomly selected bacterial pathogens from the Steve Biko Academic Hospital", FEMS Immunol Med Microbiol, 56, pp.191~196 (2009)
- Sohei Harada, "Extended-spectrum β-Lactamases: Implications for the Clinical Laboratory and Therapy", Annals of Laboratory Medicine, 28(6), pp.401~412 (2008), 대한진단검사의학회
- Gupta V, "An update on newer beta-lactamases", Indian J Med Res, 126, pp.417~427 (2007)
- Pfeifer Y, "Resistance to cephalosporins and carbapenems in Gram-negative bacterial pathogens", Int J Med Microbiol, 300, pp.371~379 (2010)
- Paterson DL, "Extended-spectrum- lactamases: a clinical update", Clin Microbiol Rev, 18, pp.657~686 (2005)
- Livermore DM, "Defining an extended-spectrum beta- lactamase", Clin Microbiol Infect, 14(1), pp.3~10 (2008)
- Robin F, "TEM-109 (CMT-5), a natural complex mutant of TEM-1 beta-lactamase combining the amino acid substitutions of TEM-6 and TEM-33 (IRT-5)", Antimicrob Agents Chemother, 49, pp.4443~4447 (2005)
- Cantón R, "IRT and CMT beta-lactamases and inhibitor resistance", Clin Microbiol Infect, 14(1), pp.53~62 (2008)
- Jacoby GA, "AmpC beta-lactamases", Clin Microbiol Rev, 22, pp.161~182 (2009)
- 이학민, "Frequency of Extended-spectrum b-lactamase (ESBL) and AmpC b-lactamase Genes in Escherichia coli and Klebsiella pneumoniae over a Three-year Period in a University Hospital in Korea", Annals of Laboratory Medicine, 30(6), pp.616~623 (2010), 대한진단검사의학회
- Bush K, "A functional classification scheme for beta-lactamases and its correlation with molecular structure", Antimicrob Agents Chemother, 39, pp.1211~1233 (1995)
- Yang K, "Diagnosis and treatment of extended-spectrum and AmpC beta-lactamase-producing organisms", Ann Pharmacother, 41, pp.1427~1435 (2007)
- 김성한, "Cefepime and the inoculum effect in tests with Klebsiella pneumoniae producing plasmid-mediated AmpC-type beta-lactamase", JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 54, pp.1130~1133, OXFORD UNIV PRESS
- Livermore DM, "Strategies to overcome extended-spectrum β-lactamases (ESBLs) and AmpC β-lactamases in shigellae", Int J Antimicrob Agents, 37, pp.405~409 (2011)
- Rooney PJ, "Nursing homes as a reservoir of extended-spectrum beta-lactamase (ESBL)- producing ciprofloxacin-resistant Escherichia coli", J Antimicrob Chemother, 64, pp.635~641 (2009)
- Ben Ami R, "Influx of extended-spectrum beta-lactamase-producing Enterobacteriaceae into the hospital", Clin Infect Dis, 42, pp.925~934 (2006)
- Gudiol C, "Bacteraemia due to multidrug-resistant Gram-negative bacilli in cancer patients: risk factors, antibiotic therapy and outcomes", J AntimicrobChemother, 66, pp.657~663 (2011)
- Senol S, "Carbapenem versus fosfomycin tromethanol in thetreatment of extended-spectrum beta-lactamase-producing Escherichia coli-related complicated lower urinary tract infection", J Chemother, 22, pp.355~357 (2010)